| Not Yet Recruiting | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma NCT07502872 | Brown University | Phase 2 |
| Not Yet Recruiting | Retreatment With CTL019/CTL119 NCT04419909 | University of Pennsylvania | Phase 1 |
| Recruiting | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558 | Lyell Immunopharma, Inc. | Phase 3 |
| Recruiting | CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma NCT06850285 | Shanxi Bethune Hospital | N/A |
| Recruiting | Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) NCT06954805 | Jennifer Amengual | Phase 2 |
| Recruiting | A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies NCT06528301 | Umoja Biopharma | Phase 1 |
| Recruiting | Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas NCT06792734 | Bantam Pharmaceuticals | Phase 1 |
| Recruiting | ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL NCT06693830 | Hua-Jay J Cherng, MD | N/A |
| Recruiting | Early Assessment of Cardiac Function After Treatment With CAR-T Cells NCT06350994 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma NCT06609304 | Zhengzhou University | Phase 4 |
| Not Yet Recruiting | A Real-World Study on Extranodal Lymphoma NCT06573099 | Ruijin Hospital | — |
| Withdrawn | PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL NCT06290622 | University of Alabama at Birmingham | Phase 1 |
| Recruiting | Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma NCT06485076 | University Health Network, Toronto | N/A |
| Recruiting | CD-19 CAR-T Cell for Pediatric ALL or Lymphoma NCT06866873 | Hong Kong Children's Hospital | N/A |
| Recruiting | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies NCT06045910 | Cancer Research UK | Phase 1 / Phase 2 |
| Completed | Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) NCT06004167 | Massachusetts General Hospital | N/A |
| Recruiting | Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma NCT06381830 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Withdrawn | Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy NCT05796271 | The University of Texas Health Science Center at San Antonio | Phase 1 |
| Not Yet Recruiting | Relmacabtagene Autoleucel in Hematologic Malignancies NCT06142188 | Shanghai Ming Ju Biotechnology Co., Ltd. | — |
| Terminated | C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma NCT06210243 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Phase 1 |
| Not Yet Recruiting | Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomar NCT05834426 | Sociedad de Lucha Contra el Cáncer del Ecuador | — |
| Active Not Recruiting | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancie NCT05797233 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers NCT05940272 | Memorial Sloan Kettering Cancer Center | N/A |
| Withdrawn | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT05431179 | Oncternal Therapeutics, Inc | Phase 3 |
| Recruiting | Prospective Observational Study of Diffuse Large-cell B Lymphoma NCT06241729 | Grand Hôpital de Charleroi | — |
| Unknown | Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma NCT05651100 | Kecellitics Biotech Company Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma NCT05263583 | Cothera Bioscience, Inc | Phase 2 |
| Recruiting | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies NCT05476770 | Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 |
| Completed | STAY-STRONG Study of Exercise Training During Chemotherapy NCT05556239 | Rigshospitalet, Denmark | N/A |
| Completed | Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome NCT05510596 | University Hospital, Montpellier | N/A |
| Active Not Recruiting | A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant NCT05540340 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma NCT05421663 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Recruiting | A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas NCT05463263 | Step Pharma, SAS | Phase 1 / Phase 2 |
| Completed | Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy NCT05064787 | Pack Health | N/A |
| Withdrawn | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab o NCT04882163 | Celgene | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL NCT04594798 | University of Rochester | Phase 2 |
| Recruiting | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma NCT04884035 | Celgene | Phase 1 |
| Active Not Recruiting | FT819 in Subjects With B-cell Malignancies NCT04629729 | Fate Therapeutics | Phase 1 |
| Withdrawn | A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 NCT04556266 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma NCT04842877 | The Lymphoma Academic Research Organisation | Phase 2 |
| Completed | Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell NCT05784415 | AIDS Malignancy Consortium | — |
| Completed | A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) NCT04849416 | Eli Lilly and Company | Phase 2 |
| Unknown | Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma NCT04715217 | Shanxi Province Cancer Hospital | Phase 1 / Phase 2 |
| Unknown | Dual Target CAR-T Cells in B-cell Lymphoma NCT04723914 | YuLi | Phase 1 / Phase 2 |
| Recruiting | Phase Ib Clinical Study of Keynatinib NCT04807881 | Medolution Ltd. | Phase 1 |
| Recruiting | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cel NCT04161248 | Canadian Cancer Trials Group | EARLY_Phase 1 |
| Unknown | A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population NCT05376709 | National Taiwan University Hospital | N/A |
| Unknown | Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lympho NCT04648475 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Completed | A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cel NCT04317066 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | CAR-37 T Cells in Hematologic Malignancies NCT04136275 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Withdrawn | Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma NCT03880279 | Triumvira Immunologics, Inc. | Phase 1 / Phase 2 |
| Unknown | CAR-T Cells in the Treatment of Malignant Hematological Tumors NCT05619861 | Hebei Senlang Biotechnology Inc., Ltd. | N/A |
| Terminated | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies NCT04245722 | Fate Therapeutics | Phase 1 |
| Recruiting | Study of CAR-T Therapy in Older Patients NCT04300998 | Memorial Sloan Kettering Cancer Center | — |
| Unknown | Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma NCT04246359 | Huiqiang Huang | Phase 2 |
| Terminated | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignan NCT04160195 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma NCT04173455 | First Affiliated Hospital of Zhejiang University | Phase 1 |
| Withdrawn | QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma NCT04052061 | ImmunityBio, Inc. | Phase 1 |
| Unknown | CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma NCT04649983 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma NCT03995147 | University of Chicago | Phase 2 |
| Unknown | CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma. NCT04037566 | Xijing Hospital | Phase 1 |
| Unknown | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma NCT03921879 | Oncotartis, Inc. | Phase 1 |
| Unknown | Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma NCT04163302 | Chinese PLA General Hospital | Phase 2 |
| Completed | ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy NCT04121507 | GWT-TUD GmbH | Phase 2 |
| Unknown | R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-N NCT04152577 | Shandong Provincial Hospital | Phase 4 |
| Unknown | CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma NCT04271410 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Terminated | A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulatio NCT03593109 | Second Affiliated Hospital of Xi'an Jiaotong University | Phase 1 |
| Active Not Recruiting | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma NCT03696784 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Completed | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymp NCT03744676 | Juno Therapeutics, a Subsidiary of Celgene | Phase 2 |
| Completed | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475 NCT03598608 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Completed | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma NCT03682796 | Triphase Research and Development III Corp. | Phase 1 |
| Unknown | Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy NCT03569696 | Meirav Kedmi MD | Phase 2 |
| Withdrawn | Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Ly NCT03605589 | Children's Hospital Medical Center, Cincinnati | Phase 1 |
| Active Not Recruiting | DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged H NCT03620578 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 2 |
| Completed | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) NCT03483103 | Juno Therapeutics, a Subsidiary of Celgene | Phase 2 |
| Unknown | CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation NCT03564977 | Qingdao Central Hospital | N/A |
| Unknown | CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT NCT03685786 | Shenzhen Second People's Hospital | Phase 1 |
| Unknown | XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects NCT03598179 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Completed | Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma NCT03458546 | The University of Texas Health Science Center at San Antonio | Phase 1 |
| Unknown | Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma ( NCT03373019 | Fudan University | Phase 2 |
| Completed | Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell NCT03019055 | Medical College of Wisconsin | Phase 1 |
| Completed | Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma NCT03415399 | Eureka Therapeutics Inc. | Phase 1 |
| Unknown | Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission? NCT03681938 | Institut Paoli-Calmettes | — |
| Active Not Recruiting | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 5 NCT03162536 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 / Phase 2 |
| Active Not Recruiting | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. NCT03229200 | Pharmacyclics Switzerland GmbH | Phase 4 |
| Unknown | Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma NCT02992834 | jiangjingting | Phase 4 |
| Completed | The Clinical Implications of Immune Checkpoint Pathways in PCNSL NCT04158128 | National Taiwan University Hospital | — |
| Terminated | Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patien NCT02670317 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Unknown | AEDV Registry of Primary Cutaneous Lymphoma NCT03646422 | Fundación Academia Española de Dermatología | — |
| Unknown | Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Ly NCT02965157 | Beijing Biohealthcare Biotechnology Co.,Ltd | Phase 1 / Phase 2 |
| Completed | The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymp NCT02679196 | Karus Therapeutics Limited | Phase 1 |
| Unknown | Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool NCT02791217 | Assuta Medical Center | — |
| Completed | T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies NCT02659943 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lym NCT02592876 | Seagen Inc. | Phase 2 |
| Unknown | Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies NCT02813837 | Innovative Cellular Therapeutics Co., Ltd. | N/A |
| Terminated | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors NCT02440685 | Asana BioSciences | Phase 1 / Phase 2 |
| Terminated | Safety Study of SEA-CD40 in Cancer Patients NCT02376699 | Seagen Inc. | Phase 1 |
| Completed | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) NCT02208037 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies NCT02017613 | Rhizen Pharmaceuticals SA | Phase 1 |
| Terminated | Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Larg NCT01925612 | Seagen Inc. | Phase 2 |
| Completed | A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously NCT01414855 | Genentech, Inc. | Phase 2 |
| Completed | A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma NCT01421667 | Seagen Inc. | Phase 2 |
| Completed | Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to NCT01087294 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphom NCT01055496 | Pfizer | Phase 1 |
| Completed | Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma NCT00998946 | Spectrum Pharmaceuticals, Inc | Phase 2 |
| Completed | Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma NCT00867087 | Pfizer | Phase 2 |
| Completed | Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) NCT00864227 | Medical College of Wisconsin | Phase 2 |
| Completed | Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT NCT00849147 | Medical College of Wisconsin | Phase 2 |
| Terminated | A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphoc NCT00768339 | Aegera Therapeutics | Phase 1 / Phase 2 |
| Completed | Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituxi NCT00724971 | Pfizer | Phase 1 |
| Completed | A Phase I/II Trial of VR-CHOP in Lymphoma Patients NCT00634179 | Emory University | Phase 1 / Phase 2 |
| Completed | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL NCT00546793 | Gilead Sciences | Phase 1 / Phase 2 |
| Terminated | Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma NCT00521638 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
| Withdrawn | A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma NCT00538096 | MedImmune LLC | Phase 1 |
| Completed | A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma NCT00498043 | Hospices Civils de Lyon | Phase 2 |
| Terminated | A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcad NCT00515138 | University of California, San Francisco | EARLY_Phase 1 |
| Completed | Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell N NCT00717925 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
| Terminated | CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's NCT00455897 | Massachusetts General Hospital | Phase 2 |
| Completed | Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma NCT00394693 | Transgene | Phase 2 |
| Terminated | Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT NCT00482053 | Stanford University | Phase 2 |
| Completed | Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL NCT00379574 | Asan Medical Center | Phase 1 / Phase 2 |
| Terminated | VELCADE,Rituximab,Cyclophosphamide and Decadron NCT00413959 | Oncology Specialists, S.C. | Phase 2 |
| Terminated | DepoCyt for Active Lymphomatous or Leukemic Meningitis NCT00523939 | Duke University | Phase 2 |
| Completed | Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCT NCT00329030 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 |
| Completed | External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma NCT00271050 | The Cleveland Clinic | Phase 1 |
| Completed | Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) NCT00156013 | Oncology Specialists, S.C. | Phase 1 / Phase 2 |
| Completed | Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma NCT00577629 | Duke University | Phase 2 |
| Terminated | Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT00216164 | Hoosier Cancer Research Network | Phase 2 |
| Completed | A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma NCT00211276 | Eisai Inc. | Phase 2 |
| Terminated | Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma NCT00210366 | International Extranodal Lymphoma Study Group (IELSG) | Phase 2 |
| Completed | Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma NCT00220285 | Bayer | Phase 2 |
| Recruiting | Family Study of Lymphoproliferative Disorders NCT00626496 | Mayo Clinic | — |
| Completed | Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma NCT00073749 | Pfizer | Phase 1 |
| Completed | Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma NCT00210314 | International Extranodal Lymphoma Study Group (IELSG) | Phase 2 |
| Completed | Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG NCT00147121 | Haruhiko Fukuda | Phase 2 / Phase 3 |
| Completed | Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy NCT00038571 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymp NCT05133505 | University Hospital, Montpellier | — |
| Terminated | Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies NCT00038883 | M.D. Anderson Cancer Center | N/A |
| Completed | Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma NCT00210379 | International Extranodal Lymphoma Study Group (IELSG) | Phase 2 |
| Completed | Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG NCT00061425 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL) NCT00051025 | Eisai Inc. | Phase 2 |
| Completed | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malign NCT00051597 | Seagen Inc. | Phase 1 / Phase 2 |
| Withdrawn | A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis NCT00210340 | International Extranodal Lymphoma Study Group (IELSG) | Phase 1 |